Moreover, the subgroups analysis showed that venetoclax is also effective in FLT3-positive patients and in secondary AML, as well as in TP53-mutated cases (despite the lower incidence—47%—and median duration—5.6 months—of CR). The gene discussed is TP53; the disease is acute myeloid leukemia.